Calamos Advisors’s AstraZeneca AZN Stock Holding History

Calamos Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-31,550	Closed	-$4.84M	–	1210
2025 Q4	$4.84M	Sell	31,550 -21,250	-40%	-$3.73M	0.02%	536
2025 Q3	$7.38M	Buy	+52,800	New	+$7.99M	0.03%	476

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Calamos Advisors's AZN Position: Q2 2026 in Review

Calamos Advisors sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 33,768 shares — an estimated $6.66M sold.

Calamos Advisors first reported a position in AZN in Q3 2018 and held it in 14 quarters. The position peaked at $17.8M in Q3 2021. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Calamos Advisors reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Calamos Advisors sold 33,768 AstraZeneca shares in Q2 2026, an estimated $6.66M.
Calamos Advisors first reported a position in AstraZeneca in Q3 2018 and held it in 14 quarters.
Calamos Advisors's AstraZeneca position peaked at $17.8M in Q3 2021.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.